CLINICAL TRIALS PROFILE FOR LUMIGAN
✉ Email this page to a colleague
All Clinical Trials for LUMIGAN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00187577 ↗ | Efficacy Study of Latanoprost and Bimatoprost Solutions in Promoting Eyelash Growth in Patients With Alopecia Areata | Completed | University of California, San Francisco | N/A | 2005-06-01 | This is a single center, randomized, investigator-masked study to determine the efficacy and safety of latanoprost and bimatoprost ophthalmic solutions in promoting eyelash growth in patients who have lost their eyelashes due to alopecia areata. These medications are FDA-approved as eyedrops for patients with glaucoma who have been noted to grow longer, darker, and thicker eyelashes with their use. In this study, patients will be asked to apply these solutions to the affected eyelid margins of one eye with a sterile cotton-tipped applicator once a day. |
| NCT00273455 ↗ | Lumigan Versus Cosopt | Completed | Pharmaceutical Research Network | Phase 4 | 2006-01-01 | To compare the intraocular pressure effect and safety of the dorzolamide/timolol fixed combination given twice daily versus bimatoprost given once every evening in patients with open-angle glaucoma in patients insufficiently controlled on latanoprost monotherapy |
| NCT00705757 ↗ | The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye | Completed | Summa Health System | Phase 4 | 2008-03-01 | The purpose of this study is to study changes in skin color that may be caused by using one of the three eye medicines: Xalatan, Travatan or Lumigan. |
| NCT00773136 ↗ | Eyelash Growth From Application of Bimatoprost in Gel Suspension to the Base of the Eyelashes | Completed | University of Miami | N/A | 2008-02-01 | Objective: To determine if Lumigan (bimatoprost) causes increased lash length when used in gel suspension applied to the base of the eyelashes. Methods: Subjects recruited from the Bascom Palmer Eye Institute were screened and those who met inclusion criteria were enrolled. Each participant received two vials of gel suspension, which contained bimatoprost and normal saline, respectively, each mixed 1:1 with GonakTM gel and labeled "right eye" and "left eye" according to randomization. The suspension was applied to the eyelashes every evening on the designated eye for 6 weeks. Lash length was measured with a caliper at enrollment, at weekly intervals during the study and at 1 and 3 months after study completion. Visual acuity, ocular symptoms, intraocular pressure and photographs were documented at these same intervals. Results: The average eyelash growth in the Lumigan group was 2.01mm (vs. control average of 1.13mm) which was a statistically significant difference (p=0.009). The average intraocular pressure decreased equally in both groups (2.14 mmHg). No change in visual acuity or iris discoloration was noted in any of the subjects. Discussion: Our data showed an increase in eyelash length with use of Lumigan in gel suspension, suggesting that it may have eyelash lengthening properties. |
| NCT00847483 ↗ | Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-weeks, Masked Evaluator, Phase IV Multi-center Study in the US | Completed | Pfizer | Phase 4 | 2002-01-01 | Compare the IOP lowering properties of latanoprost, travoprost and bimatoprost |
| NCT00847483 ↗ | Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-weeks, Masked Evaluator, Phase IV Multi-center Study in the US | Completed | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Phase 4 | 2002-01-01 | Compare the IOP lowering properties of latanoprost, travoprost and bimatoprost |
| NCT01001195 ↗ | Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution | Completed | Allergan | Phase 2 | 2009-11-01 | This study will evaluate the safety, efficacy and dose-response of AGN-210669. This study will also compare AGN-210669 with bimatoprost ophthalmic solution (LUMIGAN®). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for LUMIGAN
Condition Name
Clinical Trial Locations for LUMIGAN
Trials by Country
Clinical Trial Progress for LUMIGAN
Clinical Trial Phase
Clinical Trial Sponsors for LUMIGAN
Sponsor Name
